Fig. 5

Antitumor activity of IL2-GMCSF in vivo. The percent of tumor-free mice (a), surviving mice (b) at different time points after treatment of C57BL/6 mice was assessed. The tumor was observed in the C57BL/6 mouse melanoma model after treatment with tumor cell vaccines or PBS (c). Furthermore, the percent of tumor-free mice (d), surviving mice (e) and the tumor volume (f) at different time points after treatment of nude mice was assessed. The tumor was observed in the nude mouse melanoma model after treatment (g). These experiments were repeated three times with similar results. *P < 0.05 compared with the PBS control group